Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.05USD
20 Jul 2017
Change (% chg)

-- (--)
Prev Close
$3.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
251,998
52-wk High
$3.14
52-wk Low
$0.68

CPRX.OQ

Chart for CPRX.OQ

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $255.55
Shares Outstanding(Mil.): 83.79
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 215.12 15.95
EPS (TTM): -0.21 -- --
ROI: -40.68 -7.79 -8.24
ROE: -41.23 -9.19 -7.87

BRIEF-Catalyst Pharmaceuticals files for mixed shelf of up to $150 mln

* Catalyst Pharmaceuticals Inc files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: (http://bit.ly/2tflLhO) Further company coverage:

Jul 12 2017

BRIEF-Catalyst Pharmaceuticals Q4 non-gaap loss per share $0.05 excluding items

* Catalyst pharmaceuticals announces fourth quarter and year-end 2016 financial results and provides corporate update

Mar 15 2017

UPDATE 1-Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Mar 15 2017

Catalyst Pharma's neuromuscular drug succeeds in study

Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Mar 15 2017

Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Mar 15 2017

BRIEF-Catalyst Pharmaceuticals reports positive data from investigator-sponsored trial of firdapse

* Catalyst Pharmaceuticals announces positive data from investigator-sponsored trial of firdapse® in treating musk antibody positive myasthenia gravis

Mar 15 2017

BRIEF-Biocept, Catalyst Pharma to provide liquid biopsy testing for small cell lung cancer

* Biocept and Catalyst Pharmaceuticals collaborate to provide liquid biopsy testing for small cell lung cancer to patients with Lambert Eaton Myasthenic Syndrome (LEMS)

Mar 14 2017

Earnings vs. Estimates